India's Ajanta Pharma falls as analysts say growth to moderate in H2
BUZZ-India's Ajanta Pharma falls as analysts say growth to moderate in H2 ** Ajanta PharmaAJPH.NS shares down about 3% at 3,405.30 rupees
** Stock logs biggest pct fall in over three weeks
** Growth in Africa institutional business unlikely to sustain at similar levels in H2, says Systematix (reduces rating to "hold" from "buy", TP at 3,908 rupees)
** Co maintaining FY guidance suggests some Q2 upside could be offset by H2 weakness, says Elara Capital ("reduce", TP at 3,310 rupees)
** EBITDA margin to moderate in H2 due to US competition, normalisation of institutional sales, higher investments in R&D/field force, says Motilal Oswal ("buy", TP at 4,075 rupees)
** Q2 revenue up 32.5%, net profit up 49.2%
** 14 analysts on average rate stock "buy", median TP at 3,800 rupees—LSEG-compiled data
** YTD, shares up 15.7%
(Reporting by Saikeerthi in Bengaluru)
Recent news on Ajanta Pharma
See all newsIndia's Ajanta Pharma falls as analysts say growth to moderate in H2
Brief: Ajanta Pharma Limited Sept-Quarter Consol Net Profit 3.88 Billion Rupees
India's Ajanta Pharma jumps on June quarter profit jump
Brief: Ajanta Pharma June-Quarter Consol PAT 3.34 Billion Rupees
Brief: Ajanta Pharma Receives US FDA Establishment Inspection Report For Paithan Facility